2μg(R: reducing condition, N:non-reducing condition).
Biotinylated TPBG/5T4 His&Avi Tag Protein, Human
Biotinylated TPBG/5T4 His&Avi Tag Protein, Human
Price:
Regular price
$430 USD
Regular price
Sale price
$430 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | 5T4 oncofetal antigen, Wnt-activated inhibitory factor 1 (WAIF1) |
| Accession | Q13641 |
| Amino Acid Sequence | Ser32-Ser355 with His&Avi Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 50-75kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Conjugation | Biotin |
| Tag | Avi Tag, His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1.Jiang YQ, Ma XJ, Wang YM, Feng Y, Kong Y, Huang AL, Jin ZX, Ying TL, Wu YL. Human germline-like monoclonal antibody against 5T4 enables potent ADC and CAR-T therapies for solid tumors. Acta Pharmacol Sin. 2026 May;47(5):1326-1337. |
Background
TPBG/5T4 (trophoblast glycoprotein/5T4 oncofetal antigen) is an approximately 72 kDa type I transmembrane glycoprotein whose extracellular domain forms a horseshoe-shaped rigid core composed of eight leucine-rich repeats (LRRs), with an intracellular domain containing a PDZ-interaction motif; functionally, it drives cell migration and tumor metastasis by inhibiting canonical Wnt/β-catenin signaling while simultaneously activating noncanonical Wnt pathways, regulating the CXCL12/CXCR4 chemotactic axis, and promoting epithelial-mesenchymal transition (EMT). Clinically, 5T4 is highly expressed in approximately 80% of solid tumors while being restricted in normal adult tissues, making it an ideal target for tumor immunotherapy that has been exploited in the development of vaccines (Trovax), antibody-drug conjugates (ADCs), CAR-T/TCR-T cell therapies, and superantigen fusion proteins (Naptumomab), and is closely associated with cancer stem cell properties and poor prognosis in multiple malignancies.
Picture
Picture
SDS-PAGE
ELISA
Immobilized Biotinylated TPBG/5T4 His&Avi Tag Protein, Human (Cat. No.UA016104) at 1.0μg/mL (100μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-Human 5T4 Antibody (Naptumomab) with EC50 of 0.76-1.06 ng/mL.
